FYI-Rett News Marvel Biosciences and Rett Therapy. According to Marvel, MB-204 is designed to work faster, more effectively, and at lower doses than existing treatments. The preclinical experiments that evaluated the therapy in Rett were done in a mouse model of the disease, conducted in collaboration with the International Institute for the Brain.Mice were treated daily for two weeks with either MB-204 or Daybue (trofinetide) — the only approved therapy for Rett in the U.S. and Canada.Marvel reported initial data late last year indicating that MB-204 restored more normal social interactions in the mouse model — generally outperforming Daybue — with benefits that persisted for weeks after treatment ended. Kens
NEU Price at posting:
$9.05 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)